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Background: Severe cutaneous adverse reactions to drugs (SCARs) include acute generalized exanthematous
pustulosis (AGEP), drug reaction with eosinophilia and systemic symptoms (DRESS) and epidermal necrolysis
(Stevens-Johnson syndrome–toxic epidermal necrolysis [SJS-TEN]). Because of the varied initial presentation of such
adverse drug reactions, diagnosis may be difficult and suggests overlap among SCARs. Overlapping SCARs are
defined as cases fulfilling the criteria for definite or probable diagnosis of at least 2 ADRs according to scoring
systems for AGEP, DRESS and SJS-TEN. We aimed to evaluate the prevalence of overlap among SCARs among cases
in the referral hospital in France.
Methods: We retrospectively analyzed data for 216 patients hospitalized in the referral centre over 7 years with a
discharge diagnosis of AGEP (n = 45), DRESS (n = 47), SJS-TEN (n = 80) or “drug rash” (n = 44). Each case with
detailed clinical data and a skin biopsy specimen was scored for AGEP, DRESS and SJS-TEN by use of diagnostic
scores elaborated by the RegiSCAR group.
Results: In total, 45 of 216 cases (21%) had at least 2 possible diagnoses: 35 had a single predominant diagnosis
(definite or probable), 7 had several possible diagnoses and 3 (2.1% of 145 confirmed SCARs) were overlap SCARs.
Conclusions: Despite ambiguities among SCARs, confirmed overlap cases are rare. This study did not avoid pitfalls
linked to its retrospective nature and selection bias. In the acute stage of disease, early identification of severe ADRs
can be difficult because of clinical or biologic overlapping features and missing data on histology, biology and
evolution. Retrospectively analyzing cases by use of diagnostic algorithms can lead to reliable discrimination among
AGEP, DRESS and SJS-TEN.
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Adverse cutaneous reactions to drugs are frequent, affec-
ting 2% to 3% of all hospitalized patients [1]. Only about
2% of these adverse cutaneous reactions are considered
severe [1]. The spectrum of severe cutaneous adverse reac-
tions to drugs (SCARs) include acute generalized
exanthematous pustulosis (AGEP), drug reaction with
eosinophilia and systemic symptoms (DRESS) and
epidermal necrolysis (Stevens-Johnson syndrome-SJS,* Correspondence: laurence.allanore@hmn.aphp.fr
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reproduction in any medium, provided the ortoxic epidermal necrolysis -TEN). These conditions are
defined by clinical features associatedmore or less with spe-
cific biological and histological findings [2,3].
AGEP is characterized by a pustular eruption arising
quickly after administration of the causative drug (usually
aminopenicillin, pristinamycin, diltiazem) [4,5]. DRESS,
also known as drug-induced hypersensitivity syndrome, is
a severe, systemic drug reaction most commonly asso-
ciated with aromatic anticonvulsants, allopurinol and
sulfonamides [6-8]. Patients typically present fever, facial
oedema, lymphadenopathy and morbilliform eruption,
which may progress to erythematous rash and exfoliative
dermatitis. Hematologic abnormalities, including eosino-
philia and atypical lymphocytosis, are a hallmark of the
condition. Visceral organ involvement typically manifests
as hepatitis but may include nephritis, interstitialral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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characterized by extensive epidermal loss with mucous
membrane erosions and often presents as impaired gen-
eral condition. These SCARs are defined as SJS, “transi-
tional SJS-TEN” or TEN, depending on the extent of
epidermal detachment (< 10%, 10–30%, > 30%, respect-
ively) [9]. The conditions have been strongly associated
with anti-infective sulfonamides, allopurinol, carbamaze-
pine, phenobarbital, phenytoin, oxicam, and more recently
nevirapine, lamotrigine and amifostine [10,11].
For each of these SCARs, diagnostic criteria have been
established [4,8]. These scoring systems take into account
clinical patterns (presentation, evolution), biological data
(for AGEP and DRESS) and histological findings. The
diagnostic scales are used to retrospectively score data and
with consensus to classify cases as definitive, probable,
possible or excluded.
Because the initial presentation of such adverse drug
reactions may vary, diagnosis is difficult and suggests the
possibility of overlap among SCARs. For instance, cases of
AGEP may present facial oedema, atypical targets or blis-
ters [12,13], and 20% of cases may show mucous involve-
ment [4]. Early descriptions of AGEP pointed to non-rare
suspicion of TEN with a confluence of pustules resulting
in superficial detachment, and even recently AGEP cases
similar to TEN were reported [14]. Elevated neutrophil
count may be accompanied by mild eosinophilia in up to
one-third of cases in certain series [15]. Internal organ in-
volvement is not common in AGEP, although lymph-node
enlargement [15], slightly reduced creatinine clearance or
slight elevation of liver enzyme levels may be observed [4].
Concerning DRESS, pustules may be found in up to
20% of cases [16]. Vesicles, blisters, atypical target lesions
or mucous membrane involvement have been reported
[6], occasionally with mild mucosal erosions [17]. Cases of
“overlap” between DRESS and TEN have been reported,
which suggests the difficulty in classifying these SCARs
under certain circumstances [18].
Finally, in SJS-TEN, internal organ involvement is not
rare and can include elevated levels of liver enzymes,
eosinophilia, and transitory proteinuria [19-21].Table 1 Details of missing data by adverse reactions
Number of cases




Cases includedTherefore, because several conditions are suspected,
clinicians may have difficulty diagnosing these SCARs [22].
Cases of overlapping SCARs – fulfilling diagnostic criteria
for different SCARs – may exist. We investigated cases of
SCARs in our referral center to determine prevalence of
overlapping SCARs, defined as fulfilling the criteria for
definite or probable diagnosis of at least two ADRs accor-
ding to scoring systems for AGEP, DRESS and SJS-TEN.Patients and methods
Selection of cases
We conducted a retrospective monocentric study of all
patients hospitalised in our department between January
1, 2000 and December 31, 2006 with a discharge diagnosis
of AGEP, DRESS, SJS-TEN or “drug rash not otherwise
specified” and with an available skin biopsy. Exclusion cri-
teria were missing data concerning clinical presentation or
biological results and wrong discharge diagnosis.
We collected clinical and epidemiological data on
demographic characteristics, exposure to drugs, clinical
presentation of the SCAR (maximal body temperature,
lymph node enlargement, duration and description of
the rash, mucosal involvement, presence of erosions and
extent), biological data (e.g., leucocyte counts, hepatic
and renal function, serological data, blood cultures) and
pathology results of skin biopsy.Classification of cases
Three of us (JCR, LVA, SB) used predefined RegiSCAR
algorithms [4,8] to assess drug causality with clinical
data from the patient’s file or clinical pictures, as well as
pathology reports, with blinding to exposure to risk fac-
tors, patient identity and biological data.
Each case was scored for AGEP, DRESS and SJS-TEN
and classified as definitive, probable, or possible AGEP,
DRESS or SJS-TEN or excluded. Overlap SCARs were
defined as cases fulfilling the criteria for definite or
probable diagnosis of at least 2 ADRs according to the
scoring systems. Data were entered into Excel spread-
sheets and checked for entry-related errors.AGEP DRESS SJS-TEN Drug rash Total
64 78 111 130 383
2 2 3 1 8
1 1 - 12 14
1 1 8 2 12
4 4 11 15 34
15 27 35 56 133
45 47 80 44 216
Suspicion of overlap
















Figure 2 Results of the validation : several diagnosis are at
least possible.
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Among 383 patient cases with a discharge diagnosis of
AGEP, DRESS, SJS-TEN or “drug rash”, only 250 were
selected because a skin biopsy specimen was available.
Data for 34 cases were excluded because of missing data
for clinical presentation or biological results or wrong
discharge diagnosis (Table 1). Eventually, 216 cases were
analysed: 45 cases with a discharge diagnosis of AGEP,
47 with DRESS, 80 with SJS-TEN and 44 with drug
rashes. The flow chart of the selection of cases is in
Figure 1.
According to the scoring systems, among these 216
cases, 181 cases had at least one possible diagnosis: 107
had only one diagnosis (with definite or probable dis-
ease), 35 had 3 excluded diagnoses, 29 had a possible
single diagnosis. The remaining 45 (21%) had several
possible, distinct SCARs (possible, probable or definite)
(Figure 2). Among the 45 cases, 35 had a single predom-
inant diagnosis (definite or probable), 7 had several pos-
sible diagnoses and 3 (2.1% of confirmed 145 confirmed
SCARs cases) were “true” overlap, with definite or prob-
able diagnosis of 2 distinct SCARs: one overlap between
AGEP and DRESS and 2 overlaps between SJS-TEN and
DRESS (Figure 3).
Discussion
Because the initial presentation of severe adverse drug
reactions may vary, diagnosis may be difficult in that
several conditions may be suspected. Our retrospective
study of cases of SCARs in our referral centre revealed
the frequent occurrence (n = 45; 21%) of SCARs cases of
several possible diagnoses (possible, probable or certain),
which reflects the clinical ambiguity among several
SCARs. In such situations, the clinician is confrontedInclusion flow chart
Cases with discharge diagnosis of 














AGEP(45), DRESS (47), SJS-TEN (80), drug rash (44)
Figure 1 Flow chart of selection of cases in the study.with an uncertain diagnosis of several disease entities.
For these 45 cases, when several diagnoses were at least
possible, the retrospective assignment of a score often
led to a single final diagnosis. Indeed, for 35 of the 45
cases, we could establish a single predominant diagnosis
(probable or definite), with one (or several) other pos-
sible diagnosis(es). Seven of the 10 remaining cases
could not be classified because several SCARs were pos-
sible. Only 3 “true” overlap SCARs were documented,
representing 2.1% of the 145 confirmed cases of SCARs.
Finally, for the patient with a severe cutaneous reac-
tion, determining the offending drug may be more im-
portant than a precise diagnosis with the reaction but is
not totally acceptable because of different risks and the
nature of long-term sequelae. Sequelae have never been
reported after AGEP, are infrequent after DRESS and
















Figure 3 Results of the validation including only probable and
definite diagnosis.
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pending on the final diagnosis.
Not all SCARs have a similar weight in the evaluation
of the benefit/risk balance by regulatory agencies and
pharmaceutical companies. The mortality rate is 10
times lower for AGEP (2%) than SJS/TEN (20–25%)
[10]. For a newly released drug, the report of one case as
“AGEP” will have a different impact than a report of
“TEN”.
The pathophysiology of drug eruption is not completely
clear. AGEP, DRESS and SJS-TEN are all categorized as
type IV reactions according to the classification by
Coombs and Gell. Type IV reactions are mediated by T
cells, causing so-called delayed hypersensitivity [25,26].
Recently, several immunohistochemical and functional
studies of drug-reactive T cells in patients with distinct
forms of SCARs revealed that distinct T-cell functions led
to different clinical phenotypes. These T cells recruit and
activate monocytes, eosinophils or neutrophils. Drug-
specific T cells also orchestrate inflammatory skin reac-
tions by releasing various cytokines and chemokines. For
instance, granulysin is the dominant cytokine inducing the
destruction of epidermis in SJS-TEN [27], eotaxine and
IL5 in DRESS [28,29], and IL-8, IL-17 and IL-22 in AGEP
[30,31]. In considering the heterogeneity of T-cell func-
tion, Pichler et al. suggested further sub-classifying
delayed hypersensitivity reactions into T-cell reactions,
which through the release of certain cytokines and chemo-
kines preferentially activate and recruit monocytes (type
IVa), eosinophils (type IVb), or neutrophils (type IVD)
[32]. Various drug-hypersensitivity diseases can be related
to the preferential activation of drug-specific T cells with
distinct functions. These complexe immune reactions are
not exclusive and may be combined. An overlap of im-
mune reactions is common, even if one type is often
dominant, and would explain clinical ambiguities among
SCARs [32,33]. Research, especially into immunological
mechanisms and pharmacogenetics, should be based on
well-characterized phenotypes and drug causality. In such
settings, diagnostic ambiguity could skew the results and
must be avoided. A striking example was the finding in
Taiwan that among carbamazepine-related SCARs, human
leukokyte antigen B*1502 positivity was associated with
all SJS or TEN cases but no cases of DRESS or mild
eruptions [34]. If investigations had been performed on all
carbamazepine-related cutaneous reactions, such clear
results would not be missed.
The limitations of this study include its retrospective
nature and selection bias. Indeed, patients hospitalized
for SCARs may show a more severe or atypical presenta-
tion. The study was monocentric, and our department is
a referral center for toxic bullous diseases, so recruit-
ment of patients may have been biased because cases are
addressed when particularly life-threatening. Cases wereselected by exhaustivity of discharge diagnosis charts
and their validity. Missing data might have caused the
loss of many cases and could contribute to underesti-
mating overlap cases. Interpretation bias was limited be-
cause clinical and histological data were scored by use of
a predefined scoring algorithm, and the review commit-
tee was blinded to patient identity and exposure to risk
factors and biological data. The strengths of this retro-
spective study are its exhaustiveness and use of pre-
established diagnostic scales.
Conclusions
Our results suggest that even if ambiguities among
SCARs are not rare, confirmation of overlap cases are
rare. AGEP, DRESS and SJS-TEN are distinct entities
with no evidence of a wide pathological spectrum. Differ-
entiating different SCARs may lead to quicker diagnosis
and more effective disease management.
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